Acurx Pharmaceuticals, Inc. Q1 FY2025 earnings call

• In January, closed a $2.5 million registered direct offering; received positive EMA regulatory guidance for ibezapolstat Phase 3 trial. - In February/March, new publications in J Antimicrobial Agents and Chemotherapeutics; Japanese and Indian patent offices granted patents for DNA pol IIIC inhibitors. - In March, closed a registered direct offering and private placement; in May, closed an equity line of credit with Lincoln Park Capital for up to $12 million. - Phase 2 clinical trial data on ibezapolstat accepted for publication in Lancet Microbe, highlighting high clinical cure rates, safety, and microbiome preservation.

No distinct product segments with financial performance and revenue contribution % discussed

• Cost cutting expected to continue in G&A and R&D until Phase 3 funding is secured. - Waiting for funding opportunities for Phase 3 trial, with multiple lines of funding inquiry (BARDA grants, ARPA-H application, European FDA interest).

• Forward-looking statements subject to risks and uncertainties that may cause actual results to differ materially from those in forward-looking statements. Investors should consider risks in SEC filings.

Q: Regarding recent publications on ibeza's selective activity and microbiome preserving fact, if the company plans to explore further and if complementary findings inform Phase 3 trial, and consider microbiome-related endpoints.

A: Yes, actively exploring; microbiome preservation/restoration is a secondary endpoint in Phase 3, and they're looking into pathway to approval with new administration.

Q: About G&A, R&D levels going forward, trajectory through 2025, and Phase 3 start date.

A: Cost cutting to continue until Phase 3; can't project Phase 3 start date yet as funding not secured; closed an equity line of credit for up to $12 million.